oncology
GSK and Novartis swap assets
March 1, 2015Research and Development, Sales and Marketing GSK, Mencevax, Nimenrix, Novartis, akt, merger, oncology, vaccines
GlaxoSmithKline’s planned major assets swap with Novartis has completed today as was predicted last week. Both firms announced the overhaul …
Hormone replacement therapy elevates ovarian cancer risk
February 13, 2015Research and Development, Sales and Marketing Cancer, HRT, Lancet, Oxford, oncology, ovarian
According to a new study women who undergo hormone replacement therapy nearly double their risk of developing ovarian cancer. Findings …
FDA fast-tracks Roche lung cancer drug
February 2, 2015Sales and Marketing Cancer, FDA, MPDL3280A, Roche, bladder, lung, oncology, pdl1
Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …
Roche oncology sales shine but profits dip
January 29, 2015Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4
Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
UK makes £30m investment in T-Cell cancer therapy
January 22, 2015Research and Development, Sales and Marketing Autolus, Cancer, London, T cell, UK, government, oncology, syncona
The UK is making a £30 million R&D investment into a promising new type of cancer treatment and is to …
Sanofi and Boehringer partner on biologics manufacturing
January 15, 2015Manufacturing and Production, Sales and Marketing Boehringer, Sanofi, antibodies, biologics, cardiovascular, diabetes, mabs, manufacturing, monoclonal, oncology
Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Evotec and Sanofi enter pre-clinical deal
December 3, 2014Research and Development, Sales and Marketing DiaPep277, Evotec, Sanofi, oncology, priftin, toulouse
Evotec and Sanofi have entered negotiations for a major multi-component strategic alliance worth around €250 million over the next five …
‘Postcode lottery’ still cause of many lung cancer deaths
December 3, 2014Research and Development, Sales and Marketing DoH, Roche, astranzeneca, lung cancer, nlca, oncology, pd-1
Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …
Wales Assembly facing questions over cancer
November 5, 2014Research and Development, Sales and Marketing CDF, Cancer, NHS, Wales, Welsh, assembly, drugs fund, oncology
The state of cancer services in Wales has come under increased scrutiny this week as the country’s ability to provide …
Retrospective study backs Iressa use in oesophageal cancer
November 5, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Cancer Oesophagus Gefitinib, Iressa, gefitinib, oncology
A group of oesophageal cancer patients can increase their survival by six months or more if treated with AstraZeneca’s Iressa, …
More cancer patients surviving for longer
October 31, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, bladder, breast, myeloma, oncology, ons, prostate
Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …
Celgene expands immunotherapy pipeline with Sutro
October 27, 2014Research and Development, Sales and Marketing Celgene, PD-1 and PD-L1, Q3, oncology, sutro
Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …
AZ oncology drug a ‘Phoenix from the flames’
October 27, 2014Sales and Marketing AstraZeneca, CHMP, EC, lynparza, olaparib, oncology
As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …
Cancer drug discovery system ‘broken’
October 24, 2014Research and Development, Sales and Marketing Cancer, cancer research, oncology, paul workman
The global system for discovering new cancer drugs is ‘broken’ and failing to turn scientific advances into enough innovative new …
